Post-Trial Access for Guselkumab in Participants With Familial Adenomatous Polyposis (NCT04948398) | Clinical Trial Compass
NO_LONGER_AVAILABLENot Applicable
Post-Trial Access for Guselkumab in Participants With Familial Adenomatous Polyposis
Plain-language summary
The purpose of this post-trial access (PTA) program is to provide guselkumab to participants with Familial Adenomatous Polyposis (FAP) who are experiencing clinical benefit after completing 48 weeks of treatment in Study CNTO1959COR1001.